|Dr. Laurent Fischer||Pres, CEO, Interim CMO & Director||922.92k||N/A||1964|
|Dr. Rupert D'Souza M.B.A., Ph.D.||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Kishor Peter Soparkar J.D.||Chief Operating Officer||N/A||N/A||1971|
|Mr. Heikki Jouttijarvi||Sr. VP & Head of Technical Operations||N/A||N/A||N/A|
|Dr. Brigit Riley Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Dena House||Sr. VP of HR, Organizational Devel. & Learning||N/A||N/A||N/A|
|Dr. Jim Wang Ph.D.||Sr. VP & Head of Regulatory Affairs||N/A||N/A||N/A|
|Mr. Thomas Kochy||Sr. VP and Head of Global Product Strategy & Commercial||N/A||N/A||N/A|
|Mr. Michael Steel||Sr. VP of Quality||N/A||N/A||N/A|
|Mr. Anand Reddi||VP, Head of Corp. Strategy & External Affairs and Engagement||N/A||N/A||N/A|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies, Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 10.